NCT01316263 / 2010-022560-12: A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors |
|
|
| Terminated | 2 | 21 | US, Europe | Olaratumab, LY3012207, IMC-3G3 | Eli Lilly and Company | Gastrointestinal Stromal Tumor (GIST) | 05/12 | 11/12 | | |
2018-001124-20: Efficacy of Olaratumab and Re-Treatment with Doxorubicin in anthracycline pretreated, advanced soft tissue sarcoma patients. |
|
|
| Ongoing | 2 | 60 | Europe | Dexrazoxan, Doxorubicinhydrochlorid, Concentrate for solution for infusion, Powder for solution for infusion, Lartruvo®, CARDIOXANE® | IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Lilly Deutschland GmbH, Clinigen Healthcare Limited | locally advanced (unresectable) or metastatic soft tissue sarcoma, locally advanced (unresectable) or metastatic soft tissue sarcoma, Diseases [C] - Cancer [C04] | | | | |
NCT03698227: OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients |
|
|
| Terminated | 2 | 2 | Europe | Olaratumab, Study treatment, Dexrazoxane, Doxorubicin | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Advanced Soft Tissue Sarcoma | 06/20 | 06/20 | | |
